300238 Stock Overview
Guanhao Biotech Co.,Ltd. develops, manufactures, and markets regenerative medicines and life sciences products in China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Guanhao Biotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.20 |
| 52 Week High | CN¥23.38 |
| 52 Week Low | CN¥7.48 |
| Beta | 0.37 |
| 1 Month Change | -16.29% |
| 3 Month Change | -24.78% |
| 1 Year Change | -25.02% |
| 3 Year Change | -55.94% |
| 5 Year Change | -57.97% |
| Change since IPO | -18.06% |
Recent News & Updates
Shareholder Returns
| 300238 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -8.8% | -5.9% | -4.9% |
| 1Y | -25.0% | -29.3% | -21.1% |
Return vs Industry: 300238 exceeded the CN Biotechs industry which returned -29.3% over the past year.
Return vs Market: 300238 underperformed the CN Market which returned -21.1% over the past year.
Price Volatility
| 300238 volatility | |
|---|---|
| 300238 Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.4% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300238's share price has been volatile over the past 3 months.
Volatility Over Time: 300238's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 535 | Yongming Zhang | www.guanhaobio.com |
Guanhao Biotech Co.,Ltd. develops, manufactures, and markets regenerative medicines and life sciences products in China. It offers NormalGEN, a dura repair patch; GrandNeuro, a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses.
Guanhao Biotech Co.,Ltd. Fundamentals Summary
| 300238 fundamental statistics | |
|---|---|
| Market cap | CN¥2.44b |
| Earnings (TTM) | CN¥31.01m |
| Revenue (TTM) | CN¥404.18m |
78.7x
P/E Ratio6.0x
P/S RatioIs 300238 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300238 income statement (TTM) | |
|---|---|
| Revenue | CN¥404.18m |
| Cost of Revenue | CN¥88.26m |
| Gross Profit | CN¥315.92m |
| Other Expenses | CN¥284.92m |
| Earnings | CN¥31.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 78.16% |
| Net Profit Margin | 7.67% |
| Debt/Equity Ratio | 8.0% |
How did 300238 perform over the long term?
See historical performance and comparison